4D MOLECULAR THERAPEUTICS, INC.

(FDMT)
  Report
Delayed Nasdaq  -  05/20 04:00:00 pm EDT
7.810 USD   +5.97%
05/13SVB Securities Adjusts 4D Molecular Therapeutics' Price Target to $28 from $30, Keeps Outperform Rating
MT
05/124D MOLECULAR THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
05/124D Molecular Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

4D Molecular Therapeutics Gets Fast-Track Designation for Retinal Disease Treatment

01/10/2022 | 08:30am EDT

By Chris Wack

4D Molecular Therapeutics Inc. said the U.S. Food and Drug Administration has granted Fast Track Designation for 4D-125 for treatment of patients with inherited retinal dystrophies due to defects in the RPGR gene, including X-linked Retinitis Pigmentosa.

The company said 4D-125 is a targeted and evolved R100-based product candidate, which was invented at 4DMT for efficient intravitreal delivery, and is designed to deliver a functional copy of the RPGR gene to photoreceptors in the retina.

The FDA's Fast Track process is designed to accelerate the development and review of treatments for serious and life-threatening diseases where no treatment exists or where the treatment in discovery may provide advantages over what is currently available. A drug candidate that receives Fast Track designation is eligible for more frequent communication with the FDA throughout the drug development process and a rolling and/or priority review of its marketing application if relevant criteria are met.

4D Molecular shares were up 4% to $19.51 in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

01-10-22 0830ET

All news about 4D MOLECULAR THERAPEUTICS, INC.
05/13SVB Securities Adjusts 4D Molecular Therapeutics' Price Target to $28 from $30, Keeps O..
MT
05/124D MOLECULAR THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condi..
AQ
05/124D Molecular Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended Ma..
CI
05/12Earnings Flash (FDMT) 4D MOLECULAR THERAPEUTICS Posts Q1 Revenue $1.2M
MT
05/124D Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Cor..
GL
05/124D Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Cor..
AQ
05/10TRANSCRIPT : 4D Molecular Therapeutics, Inc. Presents at Bank of America 2022 Healthcare C..
CI
05/054D Molecular Therapeutics to Participate in the BofA Securities 2022 Healthcare Confere..
GL
05/054D Molecular Therapeutics to Participate in the BofA Securities 2022 Healthcare Confere..
AQ
04/044D Molecular Therapeutics Starts Cystic Fibrosis Trial with Dosing of First Patient
MT
More news
Analyst Recommendations on 4D MOLECULAR THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 15,0 M - -
Net income 2022 -84,7 M - -
Net cash 2022 47,1 M - -
P/E ratio 2022 -2,59x
Yield 2022 -
Capitalization 252 M 252 M -
EV / Sales 2022 13,7x
EV / Sales 2023 18,5x
Nbr of Employees 137
Free-Float 88,3%
Chart 4D MOLECULAR THERAPEUTICS, INC.
Duration : Period :
4D Molecular Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends 4D MOLECULAR THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 7,81 $
Average target price 28,25 $
Spread / Average Target 262%
EPS Revisions
Managers and Directors
David H. Kirn President, Chief Executive Officer & Director
August J. Moretti Chief Financial Officer
John F. Milligan Executive Chairman
Melissa Kotterman Vice President-Discovery & Engineering
Fred Kamal Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
4D MOLECULAR THERAPEUTICS, INC.-64.40%252
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567